Tolerogenic dendritic cells (tolDCs) are explored as a promising standalone or combination therapy in type 1 diabetes (T1D). The therapeutic application of tolDCs, including in human trials, has been tested also in other autoimmune diseases, however, T1D displays some unique features. In addition, unlike in several disease-induced animal models of autoimmune diseases, the prevalent animal model for T1D, the NOD mouse, develops diabetes spontaneously. This review compares evidence of various tolDCs approaches obtained from animal (mainly NOD) models of T1D with a focus on parameters of this cell-based therapy such as protocols of tolDC preparation, antigen-specific vs. unspecific approaches, doses of tolDCs and/or autoantigens, application schemes, application routes, the migration of tolDCs as well as their preventive, early pre-onset intervention or curative effects. This review also discusses perspectives of tolDC therapy and areas of preclinical research that are in need of better clarification in animal models in a quest for effective and optimal tolDC therapies of T1D in humans.

Department of Immunology 2nd Medical School Charles University Prague Czechia

Institute of Microbiology of the Czech Academy of Sciences v v i Prague Czechia

SOTIO a s Prague Czechia

Zobrazit více v PubMed

Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev. (1994) 15:516–42. 10.1210/edrv-15-4-516 PubMed DOI

Todd JA, Knip M, Mathieu C. Strategies for the prevention of autoimmune type 1 diabetes. Diabet Med. (2011) 28:1141–3. 10.1111/j.1464-5491.2011.03400.x PubMed DOI PMC

IDF Diabetes Atlas 8th ed Brussels: International Diabetes Federation; (2017) Available online at: http://www.diabetesatlas.org

Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. results of a multicentre double-blind trial. Lancet. (1986) 8499:119–24. 10.1016/S0140-6736(86)91943-4 PubMed DOI

Nelson JL, Torrez R, Louie FM, Choe S, Storb R, Sullivan KM. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol Suppl. (1997) 48:23–9. PubMed

Al-Anazi KA, Bakhit K, Al-Sagheir A, Al-Hashmi H, Abdulbaqi M, Al-Shibani Z, et al. Cure of insulin-dependent diabetes mellitus by an autologous hematopoietic stem cell transplantation performed to control multiple myeloma in a patient with chronic renal failure on regular hemodialysis. J Stem Cell Biol Transl. (2017) 1:11 10.21767/2575-7725.100011 DOI

Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, et al. Autologous non-myeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. (2007) 297:1568–76. 10.1001/jama.297.14.1568 PubMed DOI

van Megen KM, van ‘t Wout ET, Forman SJ, Roep BO. A future for autologous hematopoietic stem cell transplantation in type 1 diabetes. Front Immunol. (2018) 9:690. 10.3389/fimmu.2018.00690 PubMed DOI PMC

Mukherjee G, Dilorenzo TP. The immunotherapeutic potential of dendritic cells in type 1 diabetes. Clin Exp Immunol. (2010) 161:197–207. 10.1111/j.1365-2249.2010.04157.x PubMed DOI PMC

Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs in mice. I. Morphology, quantification, tissue distribution. J Exp Med. (1973) 137:1142–62. 10.1084/jem.137.5.1142 PubMed DOI PMC

Steinman RM, Witmer MD. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci USA. (1978) 75:5132–6. PubMed PMC

Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. . Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. (2001) 194:769–79. 10.1084/jem.194.6.769 PubMed DOI PMC

Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA. (2002) 99:351–8. 10.1073/pnas.231606698 PubMed DOI PMC

Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. (2010) 108:111–65. 10.1016/B978-0-12-380995-7.00004-5 PubMed DOI PMC

Morel PA, Turner MS. Dendritic cells and the maintenance of self-tolerance. Immunol Res. (2011) 50:124–9. 10.1007/s12026-011-8217-y PubMed DOI

Giannoukakis N, Trucco M. A role for tolerogenic dendritic cell-induced B-regulatory cells in type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. (2012) 19:279–87. 10.1097/MED.0b013e328355461b PubMed DOI

Osorio F, Fuentes C, López MN, Salazar-Onfray F, González FE. Role of dendritic cells in the induction of lymphocyte tolerance. Front Immunol. (2015) 6:535. 10.3389/fimmu.2015.00535 PubMed DOI PMC

Ganguly D, Haak S, Sisirak V, Reizis B. The role of dendritic cells in autoimmunity. Nat Rev Immunol. (2013) 13:566–77. 10.1038/nri3477 PubMed DOI PMC

Ivanov II, Honda K. Intestinal commensal microbes as immune modulators. Cell Host Microbe. (2012) 12:496–508. 10.1016/j.chom.2012.09.009 PubMed DOI PMC

Weyd H, Abeler-Dörner L, Linke B, Mahr A, Jahndel V, Pfrang S, et al. . Annexin A1 on the surface of early apoptotic cells suppresses CD8+ T cell immunity. PLoS ONE. (2013) 8:e62449. 10.1371/journal.pone.0062449 PubMed DOI PMC

Stojanovic I, Dimitrijevic M, Vives-Pi M, Mansilla MJ, Pujol-Autonell I, Rodríguez-Fernandez S, et al. . Cell-based tolerogenic therapy, experience from animal models of multiple sclerosis, type 1 diabetes and rheumatoid arthritis. Curr Pharm Des. (2017) 23:2623–43. 10.2174/1381612823666170214120708 PubMed DOI

Trzonkowski P, Bacchetta R, Battaglia M, Berglund D, Bohnenkamp HR, ten Brinke A, et al. . Hurdles in therapy with regulatory T cells. Sci Transl Med. (2015) 7:304ps18. 10.1126/scitranslmed.aaa7721 PubMed DOI

Escobar A, Aguirre A, Guzmán MA, González R, Catalán D, Acuña-Castillo C, et al. . Tolerogenic dendritic cells derived from donors with natural rubber latex allergy modulate allergen-specific T-cell responses and IgE production. PLoS ONE. (2014) 9:e85930. 10.1371/journal.pone.0085930 PubMed DOI PMC

Li X, Yang A, Huang H, Zhang X, Town J, Davis B, et al. . Induction of type 2 T helper cell allergen tolerance by IL-10-differentiated regulatory dendritic cells. Am J Respir Cell Mol Biol. (2010) 42:190–9. 10.1165/rcmb.2009-0023OC PubMed DOI

Luckey U, Maurer M, Schmidt T, Lorenz N, Seebach B, Metz M, et al. . T cell killing by tolerogenic dendritic cells protects mice from allergy. J Clin Invest. (2011) 121:3860–71. 10.1172/JCI45963 PubMed DOI PMC

Li H, Shi B. Tolerogenic dendritic cells and their applications in transplantation. Cell Mol Immunol. (2015) 12:24–30. 10.1038/cmi.2014.52 PubMed DOI PMC

Singer BD, King LS, D'Alessio FR. Regulatory T cells as immunotherapy. Front Immunol. (2014) 5:46. 10.3389/fimmu.2014.00046 PubMed DOI PMC

Worbs T, Hammerschmidt SI, Förster R. Dendritic cell migration in health and disease. Nat Rev Immunol. (2017) 17:30–48. 10.1038/nri.2016.116 PubMed DOI

Creusot RJ, Yaghoubi SS, Chang P, Chia J, Contag CH, Gambhir SS, et al. . Lymphoid-tissue-specific homing of bone-marrow-derived dendritic cells. Blood. (2009) 113:6638–47. 10.1182/blood-2009-02-204321 PubMed DOI PMC

Creusot RJ, Giannoukakis N, Trucco M, Clare-Salzler MJ, Fathman CG. It's time to bring dendritic cell therapy to type 1 diabetes. Diabetes. (2014) 63:20–30. 10.2337/db13-0886 PubMed DOI PMC

Phillips BE, Garciafigueroa Y, Trucco M, Giannoukakis N. Clinical tolerogenic dendritic cells: exploring therapeutic impact on human autoimmune disease. Front Immunol. (2017) 8:1279. 10.3389/fimmu.2017.01279 PubMed DOI PMC

Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care. (2011) 34:2026–32. 10.2337/dc11-0472 PubMed DOI PMC

Giannoukakis N. Tolerogenic dendritic cells for type 1 diabetes. Immunotherapy. (2013) 5:569–71. 10.2217/imt.13.50 PubMed DOI

Roep B. Immune Intervention With Tolerogenic Dendritic Cells in Type 1 Diabetes. A Phase 1 Safety Study Called D-Sense. Clinical Trial no: NTR5542; Netherland Trial Info (2015). Available online at: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5542

Clare-Salzler MJ, Brooks J, Chai A, van Herle K, Anderson C. Prevention of diabetes in non-obese diabetic mice by dendritic cell transfer. J Clin Invest. (1992) 90:741–8. 10.1172/JCI115946 PubMed DOI PMC

Machen J, Harnaha J, Lakomy R, Styche A, Trucco M, Giannoukakis N. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to non-obese diabetic mouse dendritic cells. J Immunol. (2004) 173:4331–41. 10.4049/jimmunol.173.7.4331 PubMed DOI

Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes. (1999) 48:2300–8. 10.2337/diabetes.48.12.2300 PubMed DOI

Hayashi T, Yao S, Crain B, Promessi VJ, Shyu L, Sheng C, et al. . Induction of tolerogenic dendritic cells by a PEGylated TLR7 ligand for treatment of type 1 diabetes. PLoS ONE. (2015) 10:e0129867. 10.1371/journal.pone.0129867 PubMed DOI PMC

Tai N, Yasuda H, Xiang Y, Zhang L, Rodriguez-Pinto D, Yokono K, et al. . IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice. Clin Immunol. (2011) 139:336–49. 10.1016/j.clim.2011.03.003 PubMed DOI

Creusot RJ, Yaghoubi SS, Kodama K, Dang DN, Dang VH, Breckpot K, et al. . Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin Immunol. (2008) 127:176–87. 10.1016/j.clim.2007.12.009 PubMed DOI PMC

Ma L, Qian S, Liang X, Wang L, Woodward JE, Giannoukakis N, et al. . Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-κB activity. Diabetes. (2003) 52:1976–85. 10.2337/diabetes.52.8.1976 PubMed DOI

Funda DP, Goliáš J, Hudcovic T, Kozáková H, Špíšek R, Palová-Jelínková L. Antigen loading (e.g., glutamic acid decarboxylase 65) of tolerogenic DCs (tolDCs) reduces their capacity to prevent diabetes in the non-obese diabetes (NOD)-severe combined immunodeficiency model of adoptive cotransfer of diabetes as well as in NOD mice. Front Immunol. (2018) 9:290. 10.3389/fimmu.2018.00290 PubMed DOI PMC

Haase C, Yu L, Eisenbarth G, Markholst H. Antigen-dependent immunotherapy of non-obese diabetic mice with immature dendritic cells. Clin Exp Immunol. (2010) 160:331–9. 10.1111/j.1365-2249.2010.04104.x PubMed DOI PMC

Marin-Gallen S, Clemente-Casares X, Planas R, Pujol-Autonell I, Carrascal J, Carrillo J, et al. . Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes. Clin Exp Immunol. (2010) 160:207–14. 10.1111/j.1365-2249.2009.04082.x PubMed DOI PMC

Lo J, Peng RH, Barker T, Xia CQ, Clare-Salzler MJ. Peptide-pulsed immature dendritic cells reduce response to beta cell target antigens and protect NOD recipients from type 1 diabetes. Ann N Y Acad Sci. (2006) 1079:153–6. 10.1196/annals.1375.023 PubMed DOI

Gibson VB, Nikolic T, Pearce VQ, Demengeot J, Roep BO, Peakman M. Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model. Clin Exp Immunol. (2015) 182:251–60. 10.1111/cei.12687 PubMed DOI PMC

Leiter EH, Prochazka M, Coleman DL. The non-obese diabetic (NOD) mice. J Am Pathol. (1987) 128:380–3. PubMed PMC

Pearson JA, Wong FS, Wen L. The importance of the non-obese diabetic (NOD) mouse model in autoimmune diabetes. J Autoimmun. (2016) 66:76–88. 10.1016/j.jaut.2015.08.019 PubMed DOI PMC

Serreze DV, Gaedeke JW, Leiter EH. Hematopoietic stem-cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C. Proc Natl Acad Sci USA. (1993) 90:9625–9. 10.1073/pnas.90.20.9625 PubMed DOI PMC

Peng R, Bathjat K, Clare-Salzer MJ. Defective maturation of myeloid dendritic cell (DC) in NOD mice is controlled by IDD10/17/18. Ann N Y Acad Sci. (2003) 1005:184–6. 10.1196/annals.1288.023 PubMed DOI

Serreze DV, Leiter EH, Hanson MS, Christianson SW, Shultz LD, Hesselton RM, et al. Emv30null NOD-scid mice. an improved host for adaptive transfer of autoimmune diabetes and growth of human lymphohematopoietic cells. Diabetes. (1995) 44:1392–8. 10.2337/diab.44.12.1392 PubMed DOI

Haase C, Ejrnaes M, Juedes AE, Wolfe T, Markholst H, von Herrath MG. Immunomodulatory dendritic cells require autologous serum to circumvent non-specific immunosuppressive activity in vivo. Blood. (2005) 106:4225–33. 10.1182/blood-2005-03-0975 PubMed DOI PMC

Creusot RJ, Chang P, Healey DG, Tcherepanova IY, Nicolette CA, Fathman CG. A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice. Mol Ther. (2010) 18:2112–20. 10.1038/mt.2010.146 PubMed DOI PMC

Feili-Hariri M, Falkner DH, Gambotto A, Papworth GD, Watkins SC, Robbins PD, et al. Dendritic cells transduced to express interleukin-4 prevent diabetes in non-obese diabetic mice with advanced insulitis. Hum Gene Ther. (2003) 14:13–23. 10.1089/10430340360464679 PubMed DOI

Harrison LC. The prospect of vaccination to prevent type 1 diabetes. Hum Vaccin. (2005) 1:143–50. 10.4161/hv.1.4.1923 PubMed DOI

Hanninen A, Harrison LC. Mucosal tolerance to prevent type 1 diabetes: can the outcome be improved in humans? Rev Diabet Stud. (2004) 1:113–21. 10.1900/RDS.2004.1.113 PubMed DOI PMC

ten Brinke A, Hilkens CM, Cools N, Geissler EK, Hutchinson JA, Lombardi G, et al. . Clinical use of tolerogenic dendritic cells-harmonization approach in European collaborative effort. Mediators Inflamm. (2015) 2015:471719. 10.1155/2015/471719 PubMed DOI PMC

Lord P, Spiering R, Aguillon JC, Anderson AE, Appel S, Benitez-Ribas D, et al. . Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies. PeerJ. (2016) 4:e2300. 10.7717/peerj.2300 PubMed DOI PMC

Nikolic T, Welzen-Coppens JM, Leenen PJ, Drexhage HA, Versnel MA. Plasmacytoid dendritic cells in autoimmune diabetes – potential tools for immunotherapy. Immunobiology. (2009) 214:791–9. 10.1016/j.imbio.2009.06.002 PubMed DOI

Feili-Hariri M, Falkner DH, Morel PA. Regulatory Th2 response induced following adoptive transfer of dendritic cells in prediabetic NOD mice. Eur J Immunol. (2002) 32:2021–30. 10.1002/1521-4141(200207)32:7<2021::AID-IMMU2021>3.0.CO;2-J PubMed DOI

Ferreira GB, Gysemans CA, Demengeot J, da Cunha JP, Vanherwegen AS, Overbergh L, et al. . 1,25-dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NOD mice. J Immunol. (2014) 192:4210–20. 10.4049/jimmunol.1302350 PubMed DOI

Li S, Zhang M, Xiang F, Zhao J, Jiang C, Zhu J. Dendritic cells expressing BTLA induces CD8+ T cell tolerance and attenuates the severity of diabetes. Vaccine. (2011) 29:7747–51. 10.1016/j.vaccine.2011.07.125 PubMed DOI

Di Caro V, Phillips B, Engman C, Harnaha J, Trucco M, Giannoukakis N. Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice. PLoS ONE. (2014) 9:e83575. 10.1371/journal.pone.0083575 PubMed DOI PMC

Engman C, Wen Y, Meng WS, Bottino R, Trucco M, Giannoukakis N. Generation of antigen-specific Foxp3+ regulatory T-cells in vivo following administration of diabetes-reversing tolerogenic microspheres does not require provision of antigen in the formulation. Clin Immunol. (2015) 160:103–23. 10.1016/j.clim.2015.03.004 PubMed DOI

Lo J, Xia CQ, Peng R, Clare-Salzler MJ. Immature dendritic cell therapy confers durable immune modulation in an antigen-dependent and antigen-independent manner in non-obese diabetic mice. J Immunol Res. (2018) 2018:5463879 10.1155/2018/5463879 PubMed DOI PMC

Looney BM, Chernatynskaya AV, Clare-Salzler MJ, Xia CQ. Characterization of bone marrow-derived dendritic cells developed in serum-free media and their ability to prevent type 1 diabetes in non-obese diabetic mice. J Blood Disord Transfus. (2014) 5:206 10.4172/2155-9864.1000206 PubMed DOI PMC

Manirarora JN, Parnell SA, Hu YH, Kosiewicz MM, Alard P. NOD dendritic cells stimulated with Lactobacilli preferentially produce IL-10 vs. IL-12 and decrease diabetes incidence. Clin Dev Immunol. (2011) 2011:630187 10.1155/2011/630187 PubMed DOI PMC

Pujol-Autonell I, Ampudia RM, Monge P, Lucas AM, Carrascal J, Verdaguer J, et el. Immunotherapy with tolerogenic dendritic cells alone or in combination with rapamycin does not reverse diabetes in NOD mice. ISRN Endocrinol. (2013) 2013:346987 10.1155/2013/346987 PubMed DOI PMC

Gaudreau S, Guindi C, Ménard M, Benabdallah A, Dupuis G, Amrani A. GM-CSF induces bone marrow precursors of NOD mice to skew into tolerogenic dendritic cells that protect against diabetes. Cell Immunol. (2010) 265:31–6. 10.1016/j.cellimm.2010.06.010 PubMed DOI

Lewis JS, Dolgova NV, Zhang Y, Xia CQ, Wasserfall CH, Atkinson MA, et al. . A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabetic NOD mice. Clin Immunol. (2015) 160:90–102. 10.1016/j.clim.2015.03.023 PubMed DOI PMC

Thomas DC, Wong FS, Zaccone P, Green EA, Wållberg M. Protection of islet grafts through transforming growth factor-β-induced tolerogenic dendritic cells. Diabetes. (2013) 62:3132–42. 10.2337/db12-1740 PubMed DOI PMC

Feili-Hariri M, Morel PA. Phenotypic and functional characteristics of BM-derived DC from NOD and non-diabetes-prone strains. Clin Immunol. (2001) 98:133–42. 10.1006/clim.2000.4959 PubMed DOI

Wells JW, Darling D, Farzaneh Galea-Lauri J. Influence of interleukin-4 on the phenotype and function of bone marrow-derived murine dendritic cells generated under serum-free conditions. Scand J Immunol. (2005) 61:251–9. 10.1111/j.1365-3083.2005.01556.x PubMed DOI

Yokota A, Takeuchi H, Maeda N, Ohoka Y, Kato C, Song SY, et al. . GM-CSF and IL-4 synergistically trigger dendritic cells to acquire retinoic acid-producing capacity. Int Immunol. (2009) 21:361–77. 10.1093/intimm/dxp003 PubMed DOI PMC

Morel PA, Srinivas M, Turner MS, Fuschiotti P, Munshi R, Bahar I, et al. . Gene expression analysis of dendritic cells that prevent diabetes in NOD mice: analysis of chemokines and costimulatory molecules. J Leukoc Biol. (2011) 90:539–50. 10.1189/jlb.0311126 PubMed DOI PMC

Yin SY, Wang CY, Yang NS. Interleukin-4 enhances trafficking and functional activities of GM-CSF-stimulated mouse myeloid-derived dendritic cells at late differentiation stage. Exp Cell Res. (2011) 317:2210–21. 10.1016/j.yexcr.2011.06.013 PubMed DOI

Helft J, Böttcher J, Chakravarty P, Zelenay S, Huotari J, Schraml BU, et al. . GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells. Immunity. (2015) 42:1197–211. 10.1016/j.immuni.2015.05.018 PubMed DOI

D'Amico A, Wu L. The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3. J Exp Med. (2003) 198:293–303. 10.1084/jem.20030107 PubMed DOI PMC

Xiao Y, Palomero J, Grabowska J, Wang L, de Rink I, van Helvert L, et al. . Macrophages and osteoclasts stem from a bipotent progenitor downstream of a macrophage/osteoclast/dendritic cell progenitor. Blood Adv. (2017) 1:1993–2006. 10.1182/bloodadvances.2017008540 PubMed DOI PMC

Naranjo-Gómez M, Raïch-Regué D, Oñate C, Grau-López L, Ramo-Tello C, Pujol-Borrell R, et al. . Comparative study of clinical grade human tolerogenic dendritic cells. J Transl Med. (2011) 9:89. 10.1186/1479-5876-9-89 PubMed DOI PMC

van Etten E, Dardenne O, Gysemans C, Overbergh L, Mathieu C. 1,25-dihydroxyvitamin D3 alters the profile of bone marrow-derived dendritic cells of NOD mice. Ann N Y Acad Sci. (2004) 1037:186–92. 10.1196/annals.1337.030 PubMed DOI

Agger R, Petersen MS, Toldbod HE, Holtz S, Dagnaes-Hansen F, Johnsen BW, et al. . Characterization of murine dendritic cells derived from adherent blood mononuclear cells in vitro. Scand J Immunol. (2000) 52:138–47. 10.1046/j.1365-3083.2000.00760.x PubMed DOI

Fekete N, Béland AV, Campbell K, Clark SL, Hoesli CA. Bags vs. flasks: a comparison of cell culture systems for the production of dendritic cell-based immunotherapies. Transfusion. (2018) 58:1800–13. 10.1111/trf.14621 PubMed DOI

Harnaha J, Machen J, Wright M, Lakomy R, Styche A, Trucco M, et al. . Interleukin-7 is a survival factor for CD4+ CD25+ T-cells and is expressed by diabetes-suppressive dendritic cells. Diabetes. (2006) 55:158–70. 10.2337/diabetes.55.01.06.db05-0340 PubMed DOI

Phillips B, Nylander K, Harnaha J, Machen J, Lakomy R, Styche A, et al. . A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes. (2008) 57:1544–55. 10.2337/db07-0507 PubMed DOI PMC

Dáňová K, Grohová A, Strnadová P, Funda DP, Šumník Z, Lebl J, et al. . Tolerogenic dendritic cells from poorly compensated type 1 diabetes patients have decreased ability to induce stable antigen-specific T cell hyporesponsiveness and generation of suppressive regulatory T cells. J Immunol. (2017) 198:729–40. 10.4049/jimmunol.1600676 PubMed DOI

Dáňová K, Klapetková A, Kayserová J, Šedivá A, Špíšek R, Jelínková LP. NF-κB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment. Oncotarget. (2015) 6:14123–38. 10.18632/oncotarget.4234 PubMed DOI PMC

Sochorová K, Budinský V, Rozková D, Tobiasová Z, Dusilová-Silková S, Špíšek R, et al. . Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol. (2009) 133:69–77. 10.1016/j.clim.2009.06.011 PubMed DOI

Nikolic T, Woittiez NJC, van der Slik A, Laban S, Joosten A, Gysemans C, et al. Differential transcriptome of tolerogenic vs. inflammatory dendritic cells points to modulated T1D genetic risk and enriched immune regulation. Genes Immun. (2017) 18:176–83. 10.1038/gene.2017.18 PubMed DOI

Vanherwegen AS, Eelen G, Ferreira GB, Ghesquière B, Cook DP, Nikolic T, et al. . Vitamin D controls the capacity of human dendritic cells to induce functional regulatory T cells by regulation of glucose metabolism. J Steroid Biochem Mol Biol. (2018) 187:134–45. 10.1016/j.jsbmb.2018.11.011 PubMed DOI

Ruffner MA, Robbins PD. Dendritic cells transduced to express interleukin 4 reduce diabetes onset in both normoglycemic and prediabetic non-obese diabetic mice. PLoS ONE. (2010) 5:e11848 10.1371/journal.pone.0011848 PubMed DOI PMC

Besin G, Gaudreau S, Ménard M, Guindi C, Dupuis G, Amrani A. Thymic stromal lymphopoietin and thymic stromal lymphopoietic-conditioned dendritic cells induce regulatory T-cell differentiation and protection of NOD mice against diabetes. Diabetes. (2008) 57:2107–17. 10.2337/db08-0171 PubMed DOI PMC

Zhang C, Zou X, Leluo G, Xu J, Xiang M. Prevention of type 1 diabetes by immature dendritic cells treated with an ethanol extract of Paecilomyces hepiali Chen mycelium. Methods Find Exp Clin Pharmacol. (2008) 30:421–9. 10.1358/mf.2008.30.6.1186083 PubMed DOI

Simon T, Pogu S, Tardif V, Rigaud K, Rémy S, Piaggio E, et al. . Carbon monoxide-treated dendritic cells decrease β1-integrin induction on CD8+ T cells and protect from type 1 diabetes. Eur J Immunol. (2013) 43:209–18. 10.1002/eji.201242684 PubMed DOI

Karumuthil-Melethil S, Perez N, Li R, Prabhakar BS, Holterman MJ, Vasu C. Dendritic cell-directed CTLA-4 engagement during pancreatic beta cell antigen presentation delays type 1 diabetes. J Immunol. (2010) 184:6695–708. 10.4049/jimmunol.0903130 PubMed DOI PMC

Warncke M, Dodero A, Dierbach H, Follo M, Veelken H. Murine dendritic cells generated under serum-free conditions have a mature phenotype and efficiently induce primary immune responses. J Immunol Methods. (2006) 310:1–11. 10.1016/j.jim.2005.09.012 PubMed DOI

Kurts C, Cannarile M, Klebba I, Brocker T. Dendritic cells are sufficient to cross-present self-antigens to CD8 T cell in vivo. J Immunol. (2001) 166:1439–42. 10.4049/jimmunol.166.3.1439 PubMed DOI

Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Eng J Med. (1994) 331:1428–36. 10.1056/NEJM199411243312107 PubMed DOI

Odumosu O, Payne K, Baez I, Jutzy J, Wall N, Langridge W. Suppression of dendritic cell activation by diabetes autoantigens linked to the cholera toxin B subunit. Immunobiology. (2011) 216:447–56. 10.1016/j.imbio.2010.09.008 PubMed DOI PMC

García-González P, Morales R, Hoyos L, Maggi J, Campos J, Pesce B, et al. . A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines. J Transl Med. (2013) 11:128. 10.1186/1479-5876-11-128 PubMed DOI PMC

Thewissen K, Broux B, Hendriks JJ, Vanhees M, Stinissen P, Slaets H, et al. Tolerogenic dendritic cells generated by in vitro treatment with SAHA are not stable in vivo. Cell Transl. (2016) 25:1207–18. 10.3727/096368915X690305 PubMed DOI

Li CH, Zhang J, Baylink DJ, Wang X, Goparaju NB, Xu Y, et al. Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydoxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis. FASEB J. (2017) 31:2996–3006. 10.1096/fj.201601243R PubMed DOI PMC

Chai L, Wu S, Liu G, Wang Z, Tian W, Ma Y. OCILRP2 signaling synergizes with LPS to induce the maturation and differentiation of murine dendritic cells. Biochem Biophys Res Commun. (2014) 446:836–42. 10.1016/j.bbrc.2014.02.145 PubMed DOI

Boks MA, Kager-Groenland JR, Haasjes MS, Zwaginga JJ, van Ham SM, ten Brinke A. IL-10-generated tolregonic dendritic cells are optimal for functional regulatory T cell induction – a comparative study of human clinical-applicable DC. Clin Immunol. (2012) 142:332–42. 10.1016/j.clim.2011.11.011 PubMed DOI

Jaakkola I, Jalkanen S, Hänninen A. Diabetogenic T cells are primed both in pancreatic and gut-associated lymph nodes in NOD mice. Eur J Immunol. (2003) 33:3255–64. 10.1002/eji.200324405 PubMed DOI

Gagnerault MC, Luan JJ, Lotton C, Lepault F. Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice. J Exp Med. (2002) 196:369–77. 10.1084/jem.20011353 PubMed DOI PMC

Jang MH, Sougawa N, Tanaka T, Hirata T, Hiroi T, Tohya K, et al. . CCR7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes. J Immunol. (2006) 176:803–10. 10.4049/jimmunol.176.2.803 PubMed DOI

Liu K, Victora GD, Schwickert TA, Guermonprez P, Meredith MM, Yao K, et al. . In vivo analysis of dendritic cell development and homeostasis. Science. (2009) 324:392–7. 10.1126/science.1170540 PubMed DOI PMC

Domogalla MP, Rostan PV, Raker VK, Steinbrink K. Tolerance through education: how tolerogenic dendritic cells shape immunity. Front Immunol. (2017) 8:1764. 10.3389/fimmu.2017.01764 PubMed DOI PMC

Sordi V, Bianchi G, Buracchi C, Mercalli A, Marchesi F, D'Amico G, et al. . Differential effects of immunosuppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: selective upregulation by rapamycin. Transplantation. (2006) 82:826–34. 10.1097/01.tp.0000235433.03554.4f PubMed DOI

Takayama T, Morelli AE, Onai N, Hirao M, Matsushima K, Tahara H, et al. . Mammalian and viral IL-10 enhance C-C chemokine receptor 5 but down-regulate C-C chemokine receptor 7 expression by myeloid dendritic cells: impact on chemotactic responses and in vivo homing ability. J Immunol. (2001) 166:7136–43. 10.4049/jimmunol.166.12.7136 PubMed DOI

Roe MM, Swain S, Sebrell TA, Sewell MA, Collins MM, Perrino BA, et al. . Differential regulation of CD103 (αE integrin) expression in human dendritic cells by retinoic acid and Toll-like receptor ligands. J Leukoc Biol. (2017) 101:1169–80. 10.1189/jlb.1MA0316-131R PubMed DOI PMC

Smyth LA, Ratnasothy K, Moreau A, Alcock S, Sagoo P, Meader L, et al. . Tolerogenic donor-derived dendritic cells risk sensitization in vivo owing to processing and presentation by recipient APCs. J Immunol. (2013) 190:4848–60. 10.4049/jimmunol.1200870 PubMed DOI PMC

Turner MS, Kane LP, Morel PA. Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion. J Immunol. (2009) 183:4895–903. 10.4049/jimmunol.0901459 PubMed DOI PMC

Funda DP, Fundova P, Han sen AK, Buschard K. Prevention or early cure of type 1 diabetes by intranasal administration of gliadin in NOD mice. PLoS ONE. (2014) 9:e94530. 10.1371/journal.pone.0094530 PubMed DOI PMC

Fousteri G, Chan JR, Zheng Y, Whiting C, Dave A, Bresson D, et al. . Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection. Diabetes. (2010) 59:3148–58. 10.2337/db10-0561 PubMed DOI PMC

McGinty JW, Marré ML, Bajzik V, Piganelli JD, James EA. T cell epitopes and post-translationally modified epitopes in type 1 diabetes. Curr Diab Rep. (2015) 15:90. 10.1007/s11892-015-0657-7 PubMed DOI PMC

Mannering SI, Di Carluccio AR, Elso CM. Neoepitopes: a new take on beta cell autoimmunity in type 1 diabetes. Diabetologia. (2018) 62:351–6. 10.1007/s00125-018-4760-6 PubMed DOI

Nguyen H, James EA. Immune recognition of citrullinated epitopes. Immunology. (2016) 149:131–8. 10.1111/imm.12640 PubMed DOI PMC

Mannering SI, Harrison LC, Williamson NA, Morris JS, Thearle DJ, Jensen KP, et al. . The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J Exp Med. (2005) 202:1191–7. 10.1084/jem.20051251 PubMed DOI PMC

Delong T, Wiles TA, Baker RL, Bradley B, Barbour G, Reisdorph R, et al. . Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science. (2016) 351:711–4. 10.1126/science.aad2791 PubMed DOI PMC

Benham H, Nel HJ, Law SC, Mehdi AM, Street S, Ramnoruth N, et al. . Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci Transl Med. (2015) 7:290ra87. 10.1126/scitranslmed.aaa9301 PubMed DOI

Chen N, Kroger CJ, Tisch RM, Bachelder EM, Ainslie KM. Prevention of type 1 diabetes with acetalated dextran microparticles containing rapamycin and pancreatic paptide P31. Adv Healthc Mater. (2018) 7:e1800341. 10.1002/adhm.201800341 PubMed DOI

Regnell SE, Lernmark Å. Early prediction of autoimmune (type 1) diabetes. Diabetologia. (2017) 60:1370–81. 10.1007/s00125-017-4308-1 PubMed DOI PMC

Langmuir PB, Bridgett MM, Bothwell AL, Crispe IN. Bone marrow abnormalities in the non-obese diabetic mouse. Int Immunol. (1993) 5:169–77. PubMed

Serreze DV, Gaskins HR, Leiter EH. Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. J Immunol. (1993) 150:2534–43. PubMed

Peng RH, Peak E, Xia CQ, Tennyson N, Clare-Salzler MJ. Heightened interferon-alpha/beta response causes myeloid cell dysfunction and promotes T1D pathogenesis in NOD mice. Ann N Y Acad Sci. (2006) 1079:99–102. 10.1196/annals.1375.013 PubMed DOI

Strid J, Lopes L, Marcinkiewicz J, Petrovska L, Nowak B, Chain BM, et al. . A defect in bone marrow derived dendritic cell maturation in the non-obesediabetic mouse. Clin Exp Immunol. (2001) 123:375–81. 10.1046/j.1365-2249.2001.01473.x PubMed DOI PMC

Poligone B, Weaver DJ, Jr, Sen P, Baldwin AS, Jr, Tisch R. Elevated NF-kappaB activation in non-obese diabetic mouse dendritic cells results in enhanced APC function. J Immunol. (2002) 168:188–96. 10.4049/jimmunol.168.1.188 PubMed DOI

Price JD, Beauchamp NM, Rahir G, Zhao Y, Rieger CC, Lau-Kilby AW, et al. . CD8+ dendritic cell-mediated tolerance of autoreative CD4+ T cells is deficient in NOD mice and can be corrected by blocking CD40L. J Leukoc Biol. (2014) 95:325–36. 10.1189/jlb.0113013 PubMed DOI PMC

Geenen V, Brilot F. Role of the thymus in the development of tolerance and autoimmunity towards the neuroendocrine system. Ann N Y Acad Sci. (2003) 992:186–95. 10.1111/j.1749-6632.2003.tb03149.x PubMed DOI

Sommandas V, Rutledge EA, Van Yserloo B, Fuller J, Lernmark Å, Drexhage HA. Aberrancies in the differentiation and maturation of dendritic cells from bone-marrow precursors are linked to various genes on chromosome 4 and other chromosome of the BB-DP rat. J Autoimmun. (2005) 25:1–12. 10.1016/j.jaut.2005.05.002 PubMed DOI

Djedovic N, Jevtić B, Mansilla MJ, Petković F, Blaževski J, Timotijević G, et al. Comparison of dendritic cells obtained from autoimmunity-prone and resistant rats. Immunobiology. (2019). 10.1016/j.imbio.2019.01.001. [Epub ahead of print] PubMed DOI

Spranger S, Frankenberger B, Schendel DJ. NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo. J Transl Med. (2012) 10:30. 10.1186/1479-5876-10-30 PubMed DOI PMC

Grohová A, Dáňová K, Špíšek R, Palová-Jelínková L. Cell based therapy for type 1 diabetes: should we take hyperglycemia into account? Front Immunol. (2019) 10:79. 10.3389/fimmu.2019.00079 PubMed DOI PMC